Ir-CPI is a protein isolated from saliva of the Ixodes ricinus tick and developed by Bioxodes for the prevention of thrombosis.

Mechanism of action

Using data from complementary sources, including epidemiological studies and investigations in various animal models, the contact pathway has emerged as a mediator of thrombosis.

Ir-CPI is the first in a novel class of antithrombotic molecules isolated from the saliva of the Ixodes ricinus tick. This ectoparasite produces salivary substances capable of modulating the host immune responses and to maintain blood in a sufficiently fluid state to acquire and digest their blood meal.

Ir-CPI was reported to link and to inhibit the activation of two components (i.e. Factor XI [FXI] and Factor XII [FXII]) of the contact phase pathway of the coagulation, a pathway essential for thrombus stabilization and growth.



Unmet medical need

Clinical practice shows that the main unmet need in the field of thrombosis prevention is the availability of an antithrombotic therapy without hemorrhage risk.


Scientific rationale for FXIIa & FXIa inhibition

Specific inhibitors of FXIIa & FXIa are promising alternatives to current antithrombotics as deficiencies in these factors protect against thrombosis without causing spontaneous bleeding, as revealed by epidemiologic and preclinical data.

The Ir-CPI market

Ir-CPI is different from existing marketed anticoagulants as it presents antithrombotic properties without disturbing the clotting balance and primary hemostasis, as showed during preclinical studies. Specific inhibition of FXIa and FXIIa positions Ir-CPI for a number of clinical indications where the contact pathway of coagulation is activated.